These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women. He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323 [TBL] [Abstract][Full Text] [Related]
6. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T; J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941 [TBL] [Abstract][Full Text] [Related]
7. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250 [TBL] [Abstract][Full Text] [Related]
11. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis. Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of POLE proofreading mutations in endometrial cancer. Church DN; Stelloo E; Nout RA; Valtcheva N; Depreeuw J; ter Haar N; Noske A; Amant F; Tomlinson IP; Wild PJ; Lambrechts D; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Creutzberg CL; Bosse T J Natl Cancer Inst; 2015 Jan; 107(1):402. PubMed ID: 25505230 [TBL] [Abstract][Full Text] [Related]
13. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation. Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107 [TBL] [Abstract][Full Text] [Related]
14. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142 [TBL] [Abstract][Full Text] [Related]
15. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. Kolehmainen A; Pasanen A; Tuomi T; Koivisto-Korander R; Bützow R; Loukovaara M PLoS One; 2020; 15(11):e0242733. PubMed ID: 33232359 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754 [TBL] [Abstract][Full Text] [Related]
17. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing. Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant Treatment for Van Gool IC; Rayner E; Osse EM; Nout RA; Creutzberg CL; Tomlinson IPM; Church DN; Smit VTHBM; de Wind N; Bosse T; Drost M Clin Cancer Res; 2018 Jul; 24(13):3197-3203. PubMed ID: 29559562 [No Abstract] [Full Text] [Related]
19. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis. Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]